Tag : TAVR

  • CONFERENCE UPDATE
    Evolut TAVR demonstrates long-term durability and safety comparable to surgical valve replacement in low-risk aortic stenosis patients

    Transcatheter aortic valve replacement (TAVR) has emerged as a transformative, minimally invasive alternative for patients with symptomatic severe aortic stenosis, irrespective of their surgical risk. The extension of TAVR into low-risk populations has warranted careful evaluation, as intermediate- and long-term comparative data assessing TAVR vs. surgery in these patients remain limited. At the ACC Annual Scientific Session 2025, Dr. Michael J. Reardon from Methodist DeBakey Heart and Vascular Center in the United States presented the 5-year outcomes from the Evolut Low Risk trial, comparing the Evolut TAVR system with surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk.